[{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Heparin Blausiegel","moa":"Antithrombin III","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VX-147","moa":"APOL-1","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Limoges","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"University Hospital, Limoges","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Limoges \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"9","companyTruncated":"University Hospital, Limoges \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Columbia University | University of British Columbia | Ohio State University | Stanford University | University of Washington | University of Michigan | University of Alabama at Birmingham | Case Western Reserve University | Cleveland Clinic | University ","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Columbia University | University of British Columbia | Ohio State University | Stanford University | University of Washington | University of Michigan | University of Alabama at Birmingham | Case Western Reserve University | Cleveland Clinic | University ","highestDevelopmentStatusID":"9","companyTruncated":"Mayo Clinic \/ Columbia University | University of British Columbia | Ohio State University | Stanford University | University of Washington | University of Michigan | University of Alabama at Birmingham | Case Western Reserve University | Cleveland Clinic | University "},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"Seoul National University Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"China Agricultural University","sponsor":"Peking University Aerospace Centre Hospital | General Hospital of Chinese Armed Police Forces | Beijing Anzhen Hospital | Beijing Biostats Technology Co. Ltd. | Beijing Heyiyuan Biotech Co. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"China Agricultural University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China Agricultural University \/ Peking University Aerospace Centre Hospital | General Hospital of Chinese Armed Police Forces | Beijing Anzhen Hospital | Beijing Biostats Technology Co. Ltd. | Beijing Heyiyuan Biotech Co. Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"China Agricultural University \/ Peking University Aerospace Centre Hospital | General Hospital of Chinese Armed Police Forces | Beijing Anzhen Hospital | Beijing Biostats Technology Co. Ltd. | Beijing Heyiyuan Biotech Co. Ltd."},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Medical Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Calcium Acetate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Fresenius Medical Care","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Fresenius Medical Care \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fresenius Medical Care \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"TRK-100STP","moa":"Prostacyclin receptor","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Astellas Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Toray Industries \/ Astellas Pharma"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"University Health Network, Toronto | Unity Health Toronto | Scarborough General Hospital | Providence Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ University Health Network, Toronto | Unity Health Toronto | Scarborough General Hospital | Providence Healthcare","highestDevelopmentStatusID":"9","companyTruncated":"Sunnybrook Health Sciences Centre \/ University Health Network, Toronto | Unity Health Toronto | Scarborough General Hospital | Providence Healthcare"},{"orgOrder":0,"company":"VieCuri Medical Centre","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Troponin, cardiac muscle | Phosphodiesterase 3","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"VieCuri Medical Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VieCuri Medical Centre \/ Orion Corporation","highestDevelopmentStatusID":"9","companyTruncated":"VieCuri Medical Centre \/ Orion Corporation"},{"orgOrder":0,"company":"Weill Cornell Medical College in Qatar","sponsor":"Hamad Medical Corporation | Weill Medical College of Cornell University","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"QATAR","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Weill Cornell Medical College in Qatar","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Cornell Medical College in Qatar \/ Hamad Medical Corporation | Weill Medical College of Cornell University","highestDevelopmentStatusID":"9","companyTruncated":"Weill Cornell Medical College in Qatar \/ Hamad Medical Corporation | Weill Medical College of Cornell University"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Serodus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NORWAY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SER150","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Serodus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Serodus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Serodus \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Jiaolian Drug Research and Development Co., Ltd","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"B007","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Jiaolian Drug Research and Development Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd"},{"orgOrder":0,"company":"Shanghai Jiaolian Drug Research and Development Co., Ltd","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"B007","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Jiaolian Drug Research and Development Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd"},{"orgOrder":0,"company":"Japan Blood Products Organization","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"GB-0998","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Japan Blood Products Organization","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Japan Blood Products Organization \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Japan Blood Products Organization \/ Undisclosed"},{"orgOrder":0,"company":"Kibow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KT-301","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Kibow Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kibow Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kibow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ebima Clifford Okundaye","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QRX-3","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Ebima Clifford Okundaye","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ebima Clifford Okundaye \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ebima Clifford Okundaye \/ Undisclosed"},{"orgOrder":0,"company":"Ebima Clifford Okundaye","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QRX-3","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Ebima Clifford Okundaye","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ebima Clifford Okundaye \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ebima Clifford Okundaye \/ Undisclosed"},{"orgOrder":0,"company":"Advicenne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ADV7103","moa":"Urinary cystine concentration","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advicenne \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Advicenne \/ Undisclosed"},{"orgOrder":0,"company":"Advicenne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ADV7103","moa":"Urinary cystine concentration","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advicenne \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Advicenne \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Beijing 302 Hospital | Beijing Anzhen Hospital | Beijing Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Beijing 302 Hospital | Beijing Anzhen Hospital | Beijing Friendship Hospital","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Hengrui Medicine \/ Beijing 302 Hospital | Beijing Anzhen Hospital | Beijing Friendship Hospital"},{"orgOrder":0,"company":"Danderyd Hospital","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Paricalcitol","moa":"Vitamin D receptor","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Danderyd Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danderyd Hospital \/ Abbott Laboratories","highestDevelopmentStatusID":"9","companyTruncated":"Danderyd Hospital \/ Abbott Laboratories"},{"orgOrder":0,"company":"Neukidney Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Eseronate","moa":"NADPH oxidase","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Neukidney Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neukidney Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neukidney Inc \/ Undisclosed"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Radboud University Medical Center \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"9","companyTruncated":"Radboud University Medical Center \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apellis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Apellis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Roberto Gedaly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veloxis Pharmaceuticals \/ Roberto Gedaly","highestDevelopmentStatusID":"9","companyTruncated":"Veloxis Pharmaceuticals \/ Roberto Gedaly"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ACI Convention
                          Not Confirmed
                          ACI Convention
                          Not Confirmed

                          Details : Pegcetacoplan is a Peptide, Unconjugated drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Glomerulosclerosis, Focal Segmental.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          October 09, 2025

                          Lead Product(s) : Pegcetacoplan

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ACI Convention
                          Not Confirmed
                          ACI Convention
                          Not Confirmed

                          Details : Povetacicept is a Protein drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Glomerulonephritis, Membranous.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 02, 2025

                          Lead Product(s) : Povetacicept

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Neukidney Inc

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Neukidney Inc

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Details : Eseronate is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Acute Kidney Injury.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 09, 2025

                          Lead Product(s) : Eseronate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Radboud University Medical Center

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Radboud University Medical Center

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Details : Obinutuzumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Glomerulonephritis, Membranous.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          September 09, 2025

                          Lead Product(s) : Obinutuzumab

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ACI Convention
                          Not Confirmed
                          ACI Convention
                          Not Confirmed

                          Details : Encaleret is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Hypocalcemia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 23, 2025

                          Lead Product(s) : Encaleret

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Ebima Clifford Okundaye

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Ebima Clifford Okundaye

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Details : QRX-3 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Renal Insufficiency, Chronic.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 10, 2025

                          Lead Product(s) : QRX-3

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Shanghai Jiaolian Drug Research and Development Co., Ltd

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Shanghai Jiaolian Drug Research and Development Co., Ltd

                          Country arrow
                          ACI Convention
                          Not Confirmed

                          Details : B007 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Primary Membranous Nephropathy.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 24, 2024

                          Lead Product(s) : B007

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Shanghai Pharmaceuticals Holding Co.,Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ACI Convention
                          Not Confirmed
                          ACI Convention
                          Not Confirmed

                          Details : Dapagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Renal Insufficiency, Chronic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 21, 2023

                          Lead Product(s) : Dapagliflozin

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Ospedale San Martino

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ACI Convention
                          Not Confirmed
                          ACI Convention
                          Not Confirmed

                          Details : Zanubrutinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Primary Membranous Nephropathy.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 31, 2023

                          Lead Product(s) : Zanubrutinib

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ACI Convention
                          Not Confirmed
                          ACI Convention
                          Not Confirmed

                          Details : XPHOZAH (tenapanor),is an investigational first-in-class phosphate absorption inhibitor, With its unique blocking MOA, XPHOZAH acts locally in gut, reducing phosphate absorption through paracellular pathway, primary pathway of phosphate absorption.

                          Product Name : Xphozah

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 03, 2022

                          Lead Product(s) : Tenapanor Hydrochloride

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank